Hindmarch Ian, Dawson Jean, Stanley Neil
HPRU Medical Research Centre, University of Surrey, School of Biomedical & Molecular Sciences, Egerton Road, Guildford, UK.
Sleep. 2005 Feb;28(2):187-93. doi: 10.1093/sleep/28.2.187.
To assess the effects of pregabalin compared with alprazolam and placebo on aspects of sleep in healthy volunteers.
Randomized, double-blind, placebo- and active-controlled, 3-way crossover.
Single research center.
Healthy adult (12 men) volunteers (N=24) received oral pregabalin 150 mg t.i.d., alprazolam 1 mg t.i.d., and placebo t.i.d. for 3 days.
Objective sleep was measured by an 8-channel polysomnograph; subjective sleep was measured using the Leeds Sleep Evaluation Questionnaire. Compared with placebo, pregabalin significantly increased slow-wave sleep both as a proportion of the total sleep period and the duration of stage 4 sleep. Alprazolam significantly reduced slow-wave sleep. Pregabalin and alprazolam produced modest, but significant, reductions in sleep-onset latency compared with placebo. Rapid eye movement sleep latency after pregabalin was no different than placebo but was significantly shorter than that found with alprazolam. Although there were no differences between the active treatments, both pregabalin and alprazolam reduced rapid eye movement sleep as a proportion of the total sleep period compared with placebo. Pregabalin also significantly reduced the number of awakenings of more than 1 minute in duration. Leeds Sleep Evaluation Questionnaire ratings of the ease of getting to sleep and the perceived quality of sleep were significantly improved following both active treatments, and ratings of behavior following awakening were significantly impaired by both drug treatments.
Pregabalin appears to have an effect on sleep and sleep architecture that distinguishes it from benzodiazepines. Enhancement of slow-wave sleep is intriguing, since reductions in slow-wave sleep have frequently been reported in fibromyalgia and general anxiety disorder.
评估与阿普唑仑和安慰剂相比,普瑞巴林对健康志愿者睡眠各方面的影响。
随机、双盲、安慰剂和活性药物对照的三交叉试验。
单一研究中心。
24名健康成年男性志愿者接受口服普瑞巴林150毫克每日三次、阿普唑仑1毫克每日三次以及安慰剂每日三次,持续3天。
通过8通道多导睡眠图测量客观睡眠;使用利兹睡眠评估问卷测量主观睡眠。与安慰剂相比,普瑞巴林显著增加了慢波睡眠,无论是占总睡眠时间的比例还是4期睡眠的时长。阿普唑仑显著减少了慢波睡眠。与安慰剂相比,普瑞巴林和阿普唑仑在入睡潜伏期方面有适度但显著的缩短。普瑞巴林后的快速眼动睡眠潜伏期与安慰剂无差异,但显著短于阿普唑仑。虽然活性药物治疗之间没有差异,但与安慰剂相比,普瑞巴林和阿普唑仑均降低了快速眼动睡眠占总睡眠时间的比例。普瑞巴林还显著减少了持续超过1分钟的觉醒次数。两种活性药物治疗后,利兹睡眠评估问卷中关于入睡难易程度和感知睡眠质量的评分均显著改善,而两种药物治疗均显著损害了觉醒后的行为评分。
普瑞巴林似乎对睡眠和睡眠结构有影响,使其有别于苯二氮䓬类药物。慢波睡眠的增强很有意思,因为在纤维肌痛和广泛性焦虑障碍中经常报告慢波睡眠减少。